Corient Private Wealth LP Makes New Investment in DaVita Inc. $DVA

Key Points

• Corient Private Wealth acquired 31,117 DaVita shares worth approximately $6.9 million in the second quarter, while institutional investors collectively own 90.12% of the company.
• Analyst views remain mixed, with four Buy, three Hold, and one Sell rating; the average rating is Hold with a consensus price target of $221.75.
• DaVita beat quarterly expectations, reporting $4.02 in earnings per share versus the $3.88 consensus and $3.55 billion in revenue, up 5.2% year over year.

Corient Private Wealth LP acquired a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 31,117 shares of the company's stock, valued at approximately $6,917,000.

A number of other institutional investors have also recently made changes to their positions in the stock. NewEdge Advisors LLC raised its holdings in DaVita by 20.8% during the 1st quarter. NewEdge Advisors LLC now owns 511 shares of the company's stock valued at $78,000 after buying an additional 88 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in DaVita by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 179,140 shares of the company's stock worth $27,403,000 after acquiring an additional 28,739 shares during the last quarter. Cerity Partners LLC grew its holdings in DaVita by 7.0% in the 2nd quarter. Cerity Partners LLC now owns 2,638 shares of the company's stock worth $376,000 after acquiring an additional 172 shares during the last quarter. Bank of Nova Scotia increased its position in shares of DaVita by 3.8% in the second quarter. Bank of Nova Scotia now owns 4,813 shares of the company's stock valued at $686,000 after acquiring an additional 176 shares during the period. Finally, Natixis increased its position in DaVita by 80.9% during the 2nd quarter. Natixis now owns 7,297 shares of the company's stock valued at $1,039,000 after purchasing an additional 3,264 shares during the period. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on DVA. Weiss Ratings raised shares of DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 5th. Zacks Research downgraded shares of DaVita from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Oppenheimer set a $220.00 price objective on shares of DaVita in a report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. Finally, Truist Financial decreased their target price on DaVita from $250.00 to $215.00 and set a "hold" rating for the company in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $221.75.

Insider Activity

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares of the company's stock, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 1.90% of the company's stock.

DaVita Price Performance

NYSE:DVA opened at $180.72 on Monday. The firm's 50-day moving average price is $211.96 and its 200-day moving average price is $183.37. The company has a market capitalization of $11.53 billion, a PE ratio of 14.79, a P/E/G ratio of 0.47 and a beta of 0.88. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.50 billion. During the same period last year, the company posted $2.95 EPS. DaVita's revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts anticipate that DaVita Inc. will post 14.57 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source